Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 250, Taiwan.
Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 250, Taiwan.
Aging (Albany NY). 2021 Apr 26;13(8):12046-12057. doi: 10.18632/aging.202908.
Hepatocellular carcinoma is a common type of liver cancer. Resistance to chemotherapeutic agents is a major problem in cancer therapy. MicroRNAs have been reported in cancer development and tumor growth; however, the relationship between chemoresistance and hepatocellular carcinoma needs to be fully investigated. Here, we treated hepatocellular carcinoma cell line (HA22T) with a histone deacetylase inhibitor to establish hepatocellular carcinoma-resistant cells (HDACi-R) and investigated the molecular mechanisms of chemoresistance in HCC cells. Although histone deacetylase inhibitor could not enhance cell death in HDACi-R but upregulation of miR-107 decreased cell viability both in parental cells and resistance cells, decreased the expression of cofilin-1, enhanced ROS-induced cell apoptosis, and dose-dependently sensitized HDACi-R to HDACi. Further, miR-107 upregulation resulted in tumor cell disorganization in both HA22T and HDACi-R in a mice xenograft model. Our findings demonstrated that miR-107 downregulation leads to hepatocellular carcinoma cell resistance in HDACi via a cofilin-1-dependent molecular mechanism and ROS accumulation.
肝细胞癌是一种常见的肝癌。化疗药物耐药性是癌症治疗中的一个主要问题。已经有报道称 microRNAs 参与了癌症的发生和肿瘤的生长;然而,化疗耐药性与肝细胞癌之间的关系仍需要充分研究。在这里,我们用组蛋白去乙酰化酶抑制剂处理肝癌细胞系(HA22T),建立了肝癌耐药细胞(HDACi-R),并研究了 HCC 细胞中化疗耐药的分子机制。尽管组蛋白去乙酰化酶抑制剂不能增强 HDACi-R 中的细胞死亡,但 miR-107 的上调降低了亲本细胞和耐药细胞的细胞活力,降低了 cofilin-1 的表达,增强了 ROS 诱导的细胞凋亡,并使 HDACi-R 对 HDACi 的敏感性呈剂量依赖性。此外,miR-107 的上调导致在 HA22T 和 HDACi-R 的小鼠异种移植模型中肿瘤细胞的紊乱。我们的研究结果表明,miR-107 的下调通过依赖于 cofilin-1 的分子机制和 ROS 积累导致了 HDACi 中的肝癌细胞耐药。